Cargando…

Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients?

Background : In developed or developing countries, the most common cancer in women is breast cancer with a pick in 40–50 years in Asia. Herein, we compared the association between IHC with FISH in HER2-positive breast cancer patients and affection of trastuzumab on disease free survival and overall...

Descripción completa

Detalles Bibliográficos
Autores principales: Payandeh, Mehrdad, Sadeghi, Masoud, Sadeghi, Edris, Janbakhsh, Alireza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338281/
https://www.ncbi.nlm.nih.gov/pubmed/28286614
_version_ 1782512522547429376
author Payandeh, Mehrdad
Sadeghi, Masoud
Sadeghi, Edris
Janbakhsh, Alireza
author_facet Payandeh, Mehrdad
Sadeghi, Masoud
Sadeghi, Edris
Janbakhsh, Alireza
author_sort Payandeh, Mehrdad
collection PubMed
description Background : In developed or developing countries, the most common cancer in women is breast cancer with a pick in 40–50 years in Asia. Herein, we compared the association between IHC with FISH in HER2-positive breast cancer patients and affection of trastuzumab on disease free survival and overall survival (OS). Subjects and Methods: Immunohistochemical (IHC) analysis of hormone receptors and HER2 was performed in 133 patients with breast cancer between 2003 and 2014. Patients were selected for Herceptin adjuvant treatment, according to IHC 3+ or FISH+. The specimens for pathology reports were fixed at 10% neutral-buffered formalin (pH=7.4) for 24 hours, then sliced into 4 μm sections. Results: The mean age of patients at diagnosis was 46.39 years (range, 24-78 years), 100% female. Concordance rates between IHC and FISH were 31.1% for IHC 2+ and 84.1% for IHC 3+ (p<0.001). The 87 patients had age ≤50 years and 46 patients had >50 years. Of the 133 patients, 30 patients (22.6%) had metastasis and 72 (54.1%) had right involvement. Ninety three (69.9%) patients had lymph node invasion. 48 patients (36.1%) were treated with trastuzumab and 85 (63.9%) were treated without trsastuzumab. The 10-year survival rate was 70% and the mean survival was 49 months. Conclusion: We recommend clinicians that FISH analysis is as a predictor in breast cancer patients with IHC score 2+. In contrast, FISH analysis of IHC 3+ samples was no useful. Trastuzumab therapy is effective and tolerated for breast cancer with IHC 3+ and probably IHC 2+/FISH+.
format Online
Article
Text
id pubmed-5338281
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center
record_format MEDLINE/PubMed
spelling pubmed-53382812017-03-10 Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients? Payandeh, Mehrdad Sadeghi, Masoud Sadeghi, Edris Janbakhsh, Alireza Int J Hematol Oncol Stem Cell Res Original Article Background : In developed or developing countries, the most common cancer in women is breast cancer with a pick in 40–50 years in Asia. Herein, we compared the association between IHC with FISH in HER2-positive breast cancer patients and affection of trastuzumab on disease free survival and overall survival (OS). Subjects and Methods: Immunohistochemical (IHC) analysis of hormone receptors and HER2 was performed in 133 patients with breast cancer between 2003 and 2014. Patients were selected for Herceptin adjuvant treatment, according to IHC 3+ or FISH+. The specimens for pathology reports were fixed at 10% neutral-buffered formalin (pH=7.4) for 24 hours, then sliced into 4 μm sections. Results: The mean age of patients at diagnosis was 46.39 years (range, 24-78 years), 100% female. Concordance rates between IHC and FISH were 31.1% for IHC 2+ and 84.1% for IHC 3+ (p<0.001). The 87 patients had age ≤50 years and 46 patients had >50 years. Of the 133 patients, 30 patients (22.6%) had metastasis and 72 (54.1%) had right involvement. Ninety three (69.9%) patients had lymph node invasion. 48 patients (36.1%) were treated with trastuzumab and 85 (63.9%) were treated without trsastuzumab. The 10-year survival rate was 70% and the mean survival was 49 months. Conclusion: We recommend clinicians that FISH analysis is as a predictor in breast cancer patients with IHC score 2+. In contrast, FISH analysis of IHC 3+ samples was no useful. Trastuzumab therapy is effective and tolerated for breast cancer with IHC 3+ and probably IHC 2+/FISH+. Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2017-01-01 /pmc/articles/PMC5338281/ /pubmed/28286614 Text en Copyright : © International Journal of Hematology-Oncology and Stem Cell Research & Tehran University of Medical Sciences This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Payandeh, Mehrdad
Sadeghi, Masoud
Sadeghi, Edris
Janbakhsh, Alireza
Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients?
title Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients?
title_full Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients?
title_fullStr Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients?
title_full_unstemmed Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients?
title_short Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients?
title_sort is there any concordance between of ihc with fish in her2-positive breast cancer patients?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338281/
https://www.ncbi.nlm.nih.gov/pubmed/28286614
work_keys_str_mv AT payandehmehrdad isthereanyconcordancebetweenofihcwithfishinher2positivebreastcancerpatients
AT sadeghimasoud isthereanyconcordancebetweenofihcwithfishinher2positivebreastcancerpatients
AT sadeghiedris isthereanyconcordancebetweenofihcwithfishinher2positivebreastcancerpatients
AT janbakhshalireza isthereanyconcordancebetweenofihcwithfishinher2positivebreastcancerpatients